Roche has announced encouraging results from its Phase II trial of CT-388, an experimental obesity treatment that achieved placebo-adjusted weight loss of 22.5% over 48 weeks of treatment. This announcement…
Researchers have developed an innovative deep learning model capable of accurately differentiating thyroid eye disease (TED) from orbital myositis using computed tomography (CT) imaging, potentially streamlining diagnostic processes for ophthalmologists.…
Moderna and Merck have announced promising five-year data for a groundbreaking personalized cancer treatment that combines mRNA technology with immunotherapy to prevent melanoma from returning after surgery. According to Drugs.com,…
Cancer immunotherapy represents one of modern medicine's greatest achievements, yet it's also one of its most frustrating paradoxes: a treatment that works miracles for some patients fails silently for others.…
A groundbreaking genetic study published in The Journal of Clinical Endocrinology & Metabolism and reported by ScienceDaily.com has revealed that obesity and high blood pressure don't simply increase dementia risk,…
Vera Therapeutics announced a major milestone in drug development on January 7, 2026, when the U.S. Food and Drug Administration granted Priority Review to the Biologics License Application (BLA) for…
A New Approach to a Persistent Problem Celcuity has reached a critical inflection point in its pursuit of a novel breast cancer treatment. The FDA's acceptance of gedatolisib's New Drug…
Breaking the Cycle of Prescription Dependency The opioid epidemic that has devastated American communities for decades may finally have a novel challenger. According to Bezinga.com, Mesoblast Limited announced FDA feedback…
The Three-Year Fight That Changed Everything When Giles Turner learned his postcode could determine whether he received life-saving cancer treatment, he didn't accept it quietly. His refusal to remain silent…
A comprehensive multi-omics analysis has identified the terminal ileum as a critical source of pathogenic antibody-producing cells in IgA nephropathy (IgAN), one of the most common primary glomerulonephritis worldwide. This…
A radically new type of optical sensor can identify individual cancer-related proteins in blood, a capability that could revolutionize how early-stage breast cancer is diagnosed and treated. according to Nanowerk.com,…
Young cancer patients with advanced Hodgkin lymphoma now have access to a significantly more effective treatment option that dramatically reduces their need for radiation therapy and offers superior long-term survival…
IgA nephropathy represents one of the most pressing kidney health challenges facing young adults worldwide. This progressive kidney disease develops when the immune system malfunctions, leading to kidney damage that…
Prostate cancer doesn't affect all men equally. Medical researchers have long known that men with African ancestry experience significantly higher rates and more severe outcomes than other groups. Now, according…
For decades, doctors have prescribed stimulant medications like Ritalin and Adderall to millions of children with ADHD, operating under the assumption that these drugs directly sharpen attention and concentration. But…
Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…
Menopause-related insomnia affects approximately one in four women during the menopausal transition, yet it remains significantly underdiagnosed and undertreated. A new analysis published in Maturitas journal and reported by The…
Axsome Therapeutics has reached a significant regulatory milestone with the US Food and Drug Administration's acceptance of a supplemental New Drug Application (NDA) for AXS-05 as a treatment for agitation…
Soleno Therapeutics has achieved a significant milestone in the treatment of a rare genetic disorder, announcing the publication of pivotal clinical study results for VYKAT™ XR in the prestigious Journal…
ImmunityBio's latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with standard immunotherapy could fundamentally alter…
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet, according to FiercePharma.com, Foresee Pharmaceuticals…
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement of a promising new treatment…
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
